PFE vs RMD

Pfizer Inc. remains a mature, large-cap pharmaceutical company with its market capitalization slightly declining to $154.21B. While the company pursues strategic initiatives like cost savings and continues pipeline development (Lyme vaccine, mRNA flu/COVID combo), these efforts are primarily aimed at stabilizing revenue and profitability against significant headwinds, not generating 10x growth. Th...

ResMed Inc. (RMD) remains a robust, highly profitable, and well-managed global leader in sleep apnea and respiratory care. Its Q2 fiscal 2026 results showed healthy 11% YoY revenue growth and strong margins, with a very solid balance sheet. However, this analysis specifically targets '10x growth potential within the next 3-5 years.' Given RMD's current large-cap status ($32.64B), achieving a marke...